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Background: Despite the current Centers for Medicare and Medicaid Services coverage criteria for carotid artery stenting
(CAS), consensus regarding its appropriateness in patients with carotid artery stenosis has not been reached. This is one
of the first population-based studies to use a dedicated administrative convention for the endovascular procedure to
address whether there is a cohort of patients in whom CAS is more beneficial than carotid endarterectomy (CEA).
Methods:We analyzed in-hospital mortality, postoperative stroke, and combined postoperative stoke/mortality in 47,752
CAS or CEA hospitalizations, matched by propensity score, in discharge data sets obtained from the states of New York
and California for the years 2005 to 2007. Other outcomes included postoperative complications, length of stay, and
volume-outcome relationships.
Results: For symptomatic patients undergoing CAS, rates were significantly higher for in-hospital mortality (3.7% vs
1.3%) and combined stroke/mortality (8.3% vs 4.6%) compared with CEA. For asymptomatic patients, there was no
statistical difference between mortality (0.6% vs 0.4%), stroke (2.0% vs 1.8%), or combined stroke/mortality (2.4% vs
1.9%) across the endovascular and open procedures, respectively. Postoperative respiratory and urinary complications as
well as cranial neuropathy were more common after CEA, whereas postoperative complications, including device
malfunction and hypotension, were more frequent after CAS. We did not find a volume-outcome relationship for CEA,
but one did exist for CAS.
Conclusions: In symptomatic patients with carotid artery stenosis, the most appropriate procedure appears to be CEA,
whereas CAS appears to be a suitable minimally invasive approach for asymptomatic patients. On the basis of these results
and data from recent multicenter randomized trials, the use of CAS in symptomatic patients should be approached with
caution. (J Vasc Surg 2010;52:906-13.)For decades, carotid endarterectomy (CEA) has been
an effective intervention for preventing ischemic strokes
due to significant carotid bifurcation disease. With the
advent of endovascular treatment by carotid artery stenting
(CAS), the optimal method of stroke prevention in the
modern era is under considerable debate. Despite the avail-
ability of the endovascular procedure for more than a
decade, most available data are from nonrandomized stud-
ies. Findings in the few prospective trials comparing CEA
and CAS have been mixed, with publications supporting
and refuting the superiority of the minimally invasive ap-
proach.1-5 Midterm and long-term results of a multicenter
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906randomized controlled trial performed in the United States
concluded that stenting and endarterectomy were equiva-
lent in patients deemed at high risk for surgery.6,7 Con-
versely, a large multicenter European trial was halted dur-
ing enrollment due to a high stroke rate in symptomatic
patients treated endovascularly.8
Administrative data sets have the advantage of measur-
ing how new technology fares in the community at large
rather than at selected centers. However, until the recent
adoption of the International Classification of Diseases, 9th
Revision, Clinical Modification (ICD-9-CM) code specifi-
cally designated for CAS, an accurate outcomes analysis was
not possible. In this study, we have reviewed the New York
and California state discharge databases for years 2005 to
2007. Using propensity analysis to establish matched co-
horts of patients treated with CEA and CAS, we compared
stroke and mortality rates, complications, length of stay,
and volume/outcome relationships for these two interven-
tions.
METHODS
Data sources. The study used publicly available hos-
pital discharge data sets obtained from the New York State
Health Department, Statewide Planning and Research Co-
operative System (SPARCS), and California’s Office of
Statewide Health Planning and Development (OSHPD)
for years 2005 to 2007. Unlike national administrative data
sets such as Medicare, New York and California state data-
Thr
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diagnosis that were used to separate preexisting comorbid
conditions from complications that occurred during hospi-
talization and were chosen for this analysis because they
represent a sizeable proportion of the United States’ pop-
ulation.
Patient population. Patients were selected using the
ICD-9-CM procedure code 00.63 for CAS and 38.12 for
CEA in the primary or any secondary position. Excluded
were hospitalizations with endovascular repair of endocra-
nial vessels (procedure code 39.72 any position) and ca-
rotid dissection (primary diagnoses code 443.21). We also
excluded patients who underwent another major interven-
tion (coronary artery bypass grafting, mitral or aortic valve
replacement) during the same admission because these
higher-morbidity procedures were associated more fre-
quently with adverse outcomes when combined with ca-
rotid interventions.
Patients were stratified into three groups: (1) overall or
total patient population, (2) symptomatic presentation,
and (3) asymptomatic presentation. Symptomatic presen-
tation was defined if admitting or primary diagnosis codes,
included in Table I, were POA. Critical to the accuracy of
this analysis is the proper choice of ICD-9-CM diagnosis
codes for the determination of symptomatic carotid steno-
sis. We began by surveying practitioners about the codes
that are used to determine symptomatic or asymptomatic
carotid stenosis. To further validate these choices, we then
identified a number of symptomatic and asymptomatic
patients undergoing carotid intervention through an inter-
nal database at New York Presbyterian Hospital and per-
formed a medical record evaluation to determine the ICD-
9-CM diagnosis codes that were used to describe their
presentation. This process led to the adoption of the symp-
tomatic codes included in Table I. Asymptomatic patients
were defined as those without these diagnosis codes present
at the time of admission for their carotid procedure.
Baseline comorbidities were defined using a modified
Elixhauser coding algorithm.9 Only POA diagnoses were
included as comorbidities. We compared the following
Table I. Definition of symptomatic carotid disease hospita
Revision, Clinical Modification codes
Procedure codes Pres
38.12 Carotid endarterectomy 362.3
362.84
00.63 Percutaneous insertion of
carotid artery stent(s)
433.11
433.31
434.11
434.91
435.8
435.9
434.01comorbidities in the overall, asymptomatic and symptom-atic cohorts for CEA and CAS (primary and any secondary
diagnosis): cardiac (congestive heart failure, cardiac ar-
rhythmia, valvular disease, and coronary disease), pulmo-
nary (emphysema, chronic pulmonary diseases, and respi-
ratory failure), neurologic disorder, peripheral vascular
disease (PVD), renal disease, hypertension, disorder of lipid
metabolism, diabetes, obesity, neck cancer, and other
cancer.
The following postoperative complications were cate-
gorized and compared between the propensity-matched
groups for the open and endovascular procedures (primary
and any secondary diagnosis): cardiac, nonvascular neuro-
logic, transient cerebral, respiratory, respiratory infection,
urinary infection, procedurally related infection; local com-
plications (bleeding, cranial neuropathy, device/patch
complications, including device malfunction for endovas-
cular repair, and device infection for open procedures ve-
nous thromboembolic events), and hypotension. Table II
(online only) provides a list of ICD-9-CM comorbidities
and complication codes.
Mortality and stroke. Mortality, postoperative
stroke, and combined postoperative stroke or mortality, or
both (stroke/mortality), were evaluated as our primary
outcomes. Postoperative stroke was defined if a discharge
had the ICD-9-CM code for postoperative stroke (997.02)
or if any of the following diagnoses codes were assigned
during the hospitalization: hemiplegia (342.90), intracere-
bral hemorrhage (431), cerebral embolism with infarct-
ion (434.11), cerebral artery occlusion with infarction
(434.91), aphasia (784.3), surgical complications of the
central nervous system (997.01), acute cerebrovascular
insufficiency (437.1), cerebral vascular accident (436),
and retinal arterial occlusions (362.30, 362.31, 362.32,
362.33, 362.34, 362.84). Transient cerebral ischemia
(435.8, 435.9) was evaluated as a separate postoperative
complication.
Length of stay. Mean and median lengths of stay
(LOS) for CEA and CAS were compared for propensity-
matched pairs within the overall, asymptomatic, and symp-
tomatic cohorts. We evaluated LOS for index hospitaliza-
ions based on International Classification of Diseases, 9th
admission diagnoses codes for symptomatic carotid disease
nal vascular occlusion
nal ischemia
lusion and stenosis of carotid artery with cerebral infarction
lusion and stenosis of multiple and bilateral arteries with cerebral
farction
ebral embolism with cerebral infarction
ebral artery occlusion, unspecified, with cerebral infarction
er specified transient cerebral ischemias
pecified transient cerebral ischemia: impending cerebrovascular
cident; intermittent cerebral ischemia; transient ischemic attack
ombosis of cerebral arteries with cerebral infarctionlizat
ent on
Reti
Reti
Occ
Occ
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Cer
Cer
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actions regardless of outcomes, hospitalizations free of
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veloped stroke and stroke/mortality.
Hospital volume. Annual hospital volumes in the
open and endovascular approach were divided into quin-
tiles. Trends in stroke/mortality rates with increasing vol-
ume quintiles were evaluated for CAS and CEA using
ordinary least-square regression analysis. Confidence inter-
vals for rates were calculated using normal approximation
to the binomial distribution.Multivariate models to predict
stroke/mortality after CAS or CEA included annual hospi-
tal volume in quintiles. Models are shown in Table III
(online only).
Statistical analysis. Propensity scores were used to
match CAS patients with CEA patients. Propensity analysis
is an increasingly common statistical method in large data
set comparative research10-12 and has been shown to re-
duce bias in estimates of the treatment effect in observa-
tional studies.13 The propensity score method allows re-
duction of multiple background characteristics to a single
composite characteristic, generates a propensity score, and
finally creates balanced cohorts for comparative analysis. It
consists of several steps:
● calculation of predicted probability (propensity) of receiving
one treatment vs another;
● stratification or matching patients from two different treat-
ment groups by propensity score and verification that match-
ing creates balanced cohorts; and
● straightforward estimation of the effect of treatment type on
the outcomes.
To determine the propensity score, a logistic regression
Table V. Demographics and comorbidities of patients un
endarterectomy (CEA) during 2005 to 2007 in New York
Variable
Overall
CAS CEA P
Age, mean 71.29 72.57 .0001
Male, % 60.69 57.07 .0001
Race, %
White 77.60 85.33 .0001
Black 3.28 2.67 .0121
Hispanic 7.47 6.06 .0001
Other 11.65 5.94 .0001
Hypertension, % 74.26 71.29 .0001
Cardiac, % 55.75 43.45 .0001
Hyperlipidemia, % 52.69 45.46 .0001
Diabetes, % 29.75 27.44 .0001
Peripheral vascular disease, % 16.84 14.27 .0001
Pulmonary, % 13.03 13.74 .1287
Nonvascular neurologic
disorders, % 11.64 6.57 .0001
Renal, % 8.81 6.25 .0001
Obesity, % 3.52 4.99 .0001
Neck cancer, % 2.39 0.67 .0001
Other cancers, % 1.62 1.55 .6925
Shaded areas designate a significantly higher rate or mean.
aNumber of hospitalizations by groups: Overall: CAS, 6360; CEA, 41,392.
Number of pairs after matching: overall, 5099; asymptomatic, 4353; symptmodel was developed where the dependent variable was thetype of procedure and the independent variables were
patient demographics and baseline clinical characteristics.
The fit of the propensity model to the data was assessed
using the concordance index.14 Patients who underwent an
endovascular procedure were matched 1:1 to patients who
had an open approach using individual propensity scores by
greedy match algorithm.15 The results after matching by
propensity score are described in Table IV (online only).
Before matching, CAS and CEA groups differed by
baseline characteristics, after matching the CAS and CEA
cohorts became balanced, and age was the only significantly
different covariate. However, the difference in age between
groups was not clinically significant. The differences be-
tween matched pairs were evaluated using paired t test for
continuous variables, Wilcoxon signed rank test, and the
McNemar test for binary data. Statistical analysis was per-
formed using the SAS software (SAS Institute Inc, Cary,
NC). Statistical significance was expressed by values of
P  .05.
RESULTS
Patient population. In New York and California,
6360 hospitalization for CAS and 41,392 for CEA from
2005 through 2007 were analyzed. Demographics and
comorbidities for these patients are provided in Table V.
Overall, the open cohort had more women (42.93% vs
39.31%), was older (72.57 years vs 71.29 years), and had a
higher rate of obesity compared with the endovascular
cohort. Alternatively, the CAS group had higher rates of
most comorbidities, including hypertension, hyperlipid-
emia, diabetes, peripheral vascular disease, neck cancer,
ing carotid artery stenting (CAS) or carotid
Californiaa
Asymptomatic Symptomatic
AS CEA P CAS CEA P
.46 72.56 .0001 70.08 72.65 .0001
.81 56.73 .0001 59.53 60.43 .6691
.39 85.72 .0001 79.12 81.36 .1951
.06 2.52 .0331 4.89 4.13 .3871
.54 5.91 .0001 7.01 7.53 .6582
.01 5.85 .0001 8.98 6.98 .0147
.48 71.00 .0001 72.57 74.23 .3455
.80 43.53 .0001 47.84 42.58 .0084
.99 45.14 .0001 50.41 48.65 .3822
.89 27.34 .0001 28.65 28.42 .8981
.33 14.50 .0001 13.11 11.97 .3865
.97 13.66 .1588 13.51 14.49 .4898
.63 5.74 .0001 26.18 14.86 .0001
.47 6.11 .0001 11.35 7.63 .0008
.43 4.92 .0001 4.19 5.67 .1045
.31 0.65 .0001 2.97 0.93 .0001
.60 1.48 .4871 1.76 2.28 .3763
ptomatic: CAS, 5620; CEA, 37,616. Symptomatic: CAS, 740; CEA, 3776.
c, 543.dergo
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atic cohort; however, statistical significance was lost in the
symptomatic group in comparisons of gender and obesity
as well as hypertension, hyperlipidemia, diabetes, and PVD.
After matching patients by propensity analysis, there were
no statistical distinctions in any comorbidities or gender
between the open and endovascular groups (Table V).
Asymptomatic presentation. Before their index hos-
pitalization for either procedure, 43,236 patients (91%)
were asymptomatic compared with 4516 (9%) symptomatic
patients. Before propensitymatching, the data showedCAS
to be significantly inferior to CEA in terms of stroke (2.05%
vs 1.15%, P  .0001) and stroke/mortality (2.46% vs
1.38%, P  .0001). After matching 4353 asymptomatic
patients who underwent CAS with 4353 asymptomatic
patients who underwent CEA, rates were equivalent for
mortality (0.55% vs 0.39%, P  .2743), stroke (2.04% vs
1.75% (P .3026), and stroke/mortality (2.37% vs 1.93%,
P  .1579; Table VI).
In our analysis of complications in matched asymptom-
atic pairs, CEA had an increased frequency of respiratory
complications (2.44% vs 1.38%, P .0003), urinary catheter-
related complications (1.56% vs 0.44%, P  .0001),
and cranial neuropathy (0.44% vs 0.18%, P  .0343) com-
pared with CAS. Iatrogenic hypotension (3.65% vs 1.24%,
P  .0001) was more common after the endovascular
approach. The rates of transient cerebral ischemia (0.32% vs
0.30%, P .8474) were not significantly different between
procedures (Table VII).
LOS was significantly longer after CEA than after CAS
for all asymptomatic hospitalizations (3.29 vs 2.57 days,
P  .0001) and for patients who survived and did not have
a stroke before discharge (3.05 vs 2.36 days, P  .0001).
However, there was no statistical difference in LOS be-
tween the two procedures in patients with postoperative
stroke (11.59 vs 9.13 days, P .1048) and stroke/mortal-
Table VI. Outcomes in carotid artery stenting (CAS) or
carotid endarterectomy (CEA) during 2005 to 2007 in
New York and California
Outcome No.a
CAS
(%)
CEA
(%)
Absolute
difference
(%) P
Overall 4919
Death 0.87 0.65 0.22 .2040
Stroke 2.50 2.03 0.47 .1167
Stroke/death 3.03 2.38 1.55 .0463
Asymptomatic 4353
Death 0.55 0.39 0.16 .2743
Stroke 2.04 1.75 0.29 .3026
Stroke/death 2.37 1.93 0.44 .1579
Symptomatic 543
Death 3.68 1.29 2.39 .0124
Stroke 5.71 4.05 1.66 .2164
Stroke/death 8.29 4.60 3.69 .0138
aMatched pairs by propensity analysis.ity (11.98 vs 12.69, P  .1226; Table VIII).Symptomatic presentation. After matching symp-
tomatic patients by propensity analysis, 543 pairs who
underwent CAS or CEA were identified. Mortality was
significantly higher in the CAS cohort (3.68%) compared
with CEA (1.29%, P .0124). The rates of stroke for CAS
(5.71%) compared with CEA (4.05%) did not reach signif-
icance (P  .2164). When stroke and mortality were com-
bined, CAS (8.29%) was considerably inferior to CEA
(4.60%, P  .0138; Table VI).
We found no statistical differences in the rates of post-
operative complications between procedures in symptom-
atic patients, except for nonvascular neurologic complica-
tions (2.21% for CAS vs 0.37% for CEA; described in Table
II, online only). Rates of postoperative cranial neuropathy
(0.18% vs 0%), transient cerebral ischemia (0.37% vs 0%),
device malfunction (1.29% vs 0.36%), and hypotension
(2.95% vs 1.29%) did not achieve statistical significance
(Table VII).
For all symptomatic patients, including patients with
and without postoperative stroke, LOS was 7.11 days for
the endovascular and 7.05 days for the open techniques
(P  .6024). LOS for the two interventions remained
equivalent in symptomatic patients who did not experience
stroke or death. LOS for CEA and CAS did not reach
statistical significance for symptomatic patients with post-
operative stroke (13.77 vs 7.54 days) or stroke/mortality
(13.83 vs 9.22 days; Table VIII).
Volume and outcome. The distribution of CAS did
not appear to significantly differ between the two states
included in this analysis. CAS was performed in 113 hospi-
tals in California and in 61 hospitals in New York. A low
annual volume of25CAS procedures was noted in 82% of
CAS hospitals in California vs 54% in New York.
We were able to demonstrate a volume-outcome rela-
tionship for CAS. Continuous improvement in stroke/
mortality rates with increasing volume was observed for
endovascular cases (R2 0.7326; Fig 1, A). We found
approximately a 1% decrease in stroke/mortality rates for
CEA with increasing volume from the first to second quin-
tile. However, we were not able to demonstrate a continu-
ous volume-outcome relationship for the open procedure
(R2  0.2744; Fig 1, B). After adjustment for patient
baseline comorbidities, demographics, and year of proce-
dure, we observed improvement in postoperative stroke or
mortality with increasing annual CAS hospital volume up
to 34 procedures and no volume-outcome relationship for
CEA.
DISCUSSION
The outcomes of CAS and CEA have been compared in
various trials. Although the indications for CEA are well
defined, the indications for CAS remain controversial. The
data presented here represent one of the largest direct
comparisons of these two techniques to date. This study
found that in symptomatic patients, CAS is associated with
a statistically significant increased risk of periprocedural
death or stroke (8.29%) compared with CEA (4.60%; P 
.014). It may be that the differences in outcomes found in
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by patient anatomy. One could hypothesize that internal
manipulation of an unstable plaque in symptomatic patients
may predispose them to embolization and stroke, whereas
internal manipulation of stable plaque in an asymptomatic
patient may not.16-18
The mortality rate in the propensity-matched symp-
tomatic cohort was almost three times as high in patients
treated endovascularly than in those treated with CEA. The
combined stroke/mortality rates revealed an absolute dif-
ference of approximately 3.7% favoring CEA. Ironically, at
this point in time, the only reimbursed indication for CAS
is for high-risk symptomatic patients. Yet, a major Euro-
pean study8 and now our analysis of two large data sets from
Table VII. Postoperative complications for carotid artery
propensity analysis during 2005 to 2007 in New York and
Variables
Overall, %
CAS
(n  4919)
CEA
(n  4919) P (
Cardiac 4.98 4.33 .1263
Nonvascular neurologic 0.87 0.85 .9136
TCI 0.41 0.26 .2230
Respiratory 1.69 2.72 .0004
Infection
Respiratory 0.51 0.59 .5862
Urinary 0.98 0.77 .2695
Procedure related 0.02 0.02 .99
Shock 0.02 0.02 .99
Renal 1.79 1.63 .5322
Urinary catheter 0.53 1.34 .0001
Local
Bleeding 3.40 3.42 .9559
VTE 0.10 0.10 .56
Cranial neuropathy 0.14 0.39 .0186
Device malfunction 0.41 0.12 .0060
Hypotension 3.46 1.32 .0001
TCI, Transient cerebral ischemia; VTE, venous thromboembolism.
aShaded areas designate significantly higher rates of complication.
Table VIII. Hospital length of stay by outcome for caroti
matched by propensity analysis during 2005 to 2007 in Ne
Postop outcome
Overall
CAS CEA P
All, No. 4919 4919 .0001
Mean, d 3.05 3.59
Median, d 1 2
No stroke/mortality, No. 4776 4776 .0001
Mean, d 2.79 3.42
Median, d 1 2
Stroke, No. 91 91 .0072
Mean, d 9.32 12.95
Median, d 7 9
Stroke/mortality, No. 127 127 .0191
Mean, d 12.31 12.83
Median, d 7 9
aShaded areas designate significantly longer length of stay.the United States reveal that symptomatic carotid stenosismay not be an appropriate indication for CAS. Our finding
of a dramatic and significant increased risk of stroke and
death in symptomatic patients undergoing CAS repair war-
rants re-evaluation of the patient population that may in-
deed benefit from this intervention.
The mortality rate associated with CAS in symptomatic
patients was high and in large part contributed to the
difference in outcomes between CAS and CEA. This mor-
tality rate is higher than that reported in registries or clinical
trials. However, it is important to point out that rigid
exclusion criteria are often used to select patients in these
trials, whereas similar patients treated in the community are
not excluded. Moreover, centers involved in these trials
have been selected for expertise, whereas a large number of
ing (CAS) or carotid endarterectomy (CEA) matched by
forniaa
Asymptomatic, % Symptomatic, %
S
353)
CEA
(n  4353) P
CAS
(n  543)
CEA
(n  543) P
2 4.14 .0779 5.52 6.08 .6961
4 1.26 .0126 2.21 0.37 .0075
2 0.30 .8474 0.37 0 .1573
8 2.44 .0003 5.16 3.68 .2382
4 0.57 .1138 1.84 1.29 .4669
1 0.74 .8981 3.68 2.95 .4927
2 0 .3173 0 0
2 0 .3173 0 0
5 1.65 .99 3.50 2.95 .5900
4 1.56 .0001 1.10 1.10 .99
0 3.77 .3491 3.31 4.48 .6121
7 0.14 .3173 0.37 0.00 .1573
8 0.44 .0343 0.18 0 .3173
0 0.14 .1083 1.29 0.36 .2059
5 1.24 .0001 2.95 1.29 .0606
ery stenting (CAS) or carotid endarterectomy (CEA)
ork and Californiaa
Asymptomatic Symptomatic
AS CEA P CAS CEA P
53 4353 .0001 543 543 .6024
2.57 3.29 7.11 7.05
1 2 5 5
51 4251 .0001 504 504 .6004
2.36 3.05 6.75 6.58
1 2 4 5
71 71 .1048 13 13 .2378
9.13 11.59 7.54 13.77
7 7 7 8
88 88 .1226 37 37 .0506
12.69 11.98 9.22 13.83
7 8 7 12stent
Cali
CA
n  4
4.9
0.7
0.3
1.3
0.3
0.7
0.0
0.0
1.6
0.4
3.4
0.0
0.1
0.3
3.6d art
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42CAS procedures reported here were performed in low-
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McPhee et al,19,20 who queried the Nationwide Inpatient
Sample (NIS) for CAS vs CEA, suggesting that these
outcomes may reflect what is currently achieved in the
community at large.
Conversely, there was no statistically significant advan-
tage for either procedure in matched asymptomatic pa-
tients, and the absolute difference for all primary outcomes
was 0.5%. When a minimally invasive intervention is
compared with conventional surgery, if there is equivalence
in outcomes, more often than not the patient’s choice is the
less invasive procedure. Nevertheless, other relevant factors
often affect the choice of a procedure, including its cost, the
steepness of the learning curve for the new technology, as
well as the availability of skilled interventionalists capable of
providing optimal outcomes. The asymptomatic popula-
tion in this study constituted approximately 91% of the
treated patients. Thus, these findings are relevant to a large
number of patients who will be treated for carotid artery
disease. In most reported series of patients treated for
carotid disease, at least two-thirds are asymptomatic. These
findings raise the possibility that ongoing randomized con-
trolled trials comparing CAS and CEA may well demon-
strate the benefit and safety of CAS repair in the asymptom-
atic cohort.21,22 At minimum, these data suggest that
practitioners should feel confident in encouraging active
enrollment of asymptomatic patients in current and future
trials comparing these two interventions.
There have been previous attempts to use administra-
tive data sets to compare outcomes of CEA and CAS.
Fig. In-hospital mortality and/or postoperative stroke a
in relation to annual hospital volume of carotid repair by q
equations, and R2 value are shown. The table below sh
stroke ormortality by hospital annual volume in quintiles
patient demographics, symptomatic presentation, and em
model. CAS, Carotid artery stent; CEA, carotid endarteMcPhee et al,19,20 using the NIS, reported higher rates ofstroke for both asymptomatic and symptomatic patients
undergoing CAS. The McPhee study did not use propen-
sity analysis to directly compare patient cohorts. The im-
portance of propensity-matching patients derived from
large data sets cannot be overemphasized. In Table V, it is
easily recognizable that patients treated with CAS were
higher risk than patients treated with CEA. Thus, an un-
matched or “apples to oranges” comparison unjustly fa-
vored the open procedure because the surgical intervention
was performed in a lower-risk cohort.
Also the method used by McPhee et al for defining
postoperative stroke was limited to one ICD-9-CM code:
997.02 (iatrogenic postoperative stroke). After careful and
detailed examination of individual hospitalizations within
our data set, we observed that many patients who devel-
oped postoperative neurologic events were not assigned
this ICD-9-CM code. To determine postoperative stroke,
we used a series of codes (detailed in Methods) that in-
cluded hemiplegia, intracerebral hemorrhage, cerebral em-
bolism with infarction, cerebral artery occlusion with in-
farction, and aphasia.
Lastly, compared with the McPhee analysis, the POA
status, available in the New York and California data sets,
allows assurance that these events were new and not present
before the intervention. POA flags have been used by
California and New York for many years and have recently
become a requirement by Centers for Medicare and Med-
icaid Services for all states. However, the POA indicator is
not available in the NIS database.
The results of the randomized clinical Carotid Revas-
ndovascular (A, CAS) or open (B, CEA) carotid surgery
les. Ninety-five percent confidence limits, approximation
dds ratios with corresponding 95% CL and P values of
ontrolling for baseline comorbidities, year of procedure,
ncy of hospitalization based on multivariable regression
my.fter e
uinti
ows o
after c
ergecularization Endarterectomy vs. Stent Trial (CREST) trial
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is not yet available. These results suggest that CAS may be
equivalent to CEA when a combined end point is used that
includes stroke, death, and myocardial infarction.23 These
data, once they are available for further scrutiny, may
confirm our findings, at least for asymptomatic patients.
As might be anticipated, the incidence of complications
was procedure-specific. CEA patients had significantly
higher rates of respiratory, venous thromboembolic, and
catheter-related complications. The increased incidence of
these complications may be related to intubation, greater
immobility, and Foley catheter placement, which all occur
more frequently in the open procedure. Predictably, cranial
neuropathy was also more common after CEA. Alterna-
tively, device/patch complications and hypotension were
more common in patients treated with CAS. The latter
complication is a well-recognized event that coincides with
balloon dilatation of the carotid artery sinus.
Practitioners often think that the LOS for CEA is 1 day
and similar to that of CAS. In clinical practice, however, the
mean LOS in all comers appears to be 1 day for both
procedures and is significantly longer after CEA. For pa-
tients who did not experience stroke or death, this differ-
ence was small, on average approximately 1 day. The in-
creased LOS in the overall cohort for the open procedure
was particularly evident in patients who sustained a stroke.
The findings of this study need to be considered within
the context of previously reported randomized trials. In the
Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy (SAPPHIRE) trial, the out-
comes of CAS and CEA were equivalent at medium-term
and long-term follow-up in a mixed cohort of symptomatic
and asymptomatic patients.6,7 Conversely, the Endarterec-
tomy Versus Angioplasty in Patients With Symptomatic
Severe Carotid Stenosis (EVA-3S)8 trial, which included
only symptomatic patients, was terminated early secondary
to a high rate of stroke in the endovascular cohort. The
Stent-Supported Percutaneous Angioplasty of the Carotid
Artery versus Endarterectomy (SPACE) trial, which ran-
domized symptomatic patients to open or endovascular
repair, failed to prove noninferiority of CAS compared with
CEA at 30 days, whereas outcomes were equivalent after 2
years of follow-up.24,25
Thus, despite the conclusions of three randomized
trials, the indications for endovascular repair remain un-
clear. It should be noted that these three trials enrolled a
combined number of 2075 patients, whereas the current
study evaluated the outcomes of almost 48,000 patients
treated for carotid stenosis, including6000 who received
stents (albeit, after matching by propensity score, we have
8706 asymptomatic and 1086 symptomatic patients).
Our analysis of the hospital volume/outcome relation-
ship for CAS reveals that increasing hospital volumes are
associated with a reduction in the risk of stroke and mor-
tality. These results suggest that CAS is a technically chal-
lenging procedure and its performance should be limited to
institutions with considerable experience. Conversely, we
were not able to demonstrate a substantial relationshipbetween CEA outcomes and volume. Although CEA may
be an equally technically challenging intervention, the
widespread use and longevity of this procedure appear to
have made the volume requirements less rigorous. Further-
more, the volume outcome relationship for carotid stenting
may bemore significant for symptomatic patients; however,
we were unable to make this determination secondary to
the low number of outcomes per quintile when symptom-
atic patients were stratified by volume.
Studies that use administrative data sets have a number
of limitations. There is the potential for coding errors.
However, because this analysis is a comparison of outcomes
for two procedures, we have assumed that the frequency of
coding errors will be similar between the two interventions,
allowing the comparison to remain valid.
There are also the complexities involved in differentiat-
ing complications or outcomes from preexisting disease.
Regarding this issue, New York and California data sets
allow preoperative and postoperative events to be differen-
tiated, whereas the NIS and other national databases do
not. The data that we have acquired are from only two
states; however, these two states represent approximately
19% of the United States population.26 One significant
limitation of this analysis is our inability to determine the
severity of comorbid or postoperative complications in-
cluding stroke.
We used the propensity score technique to create bal-
anced cohorts for analysis. A limitation of propensity anal-
ysis is that this method, unlike randomization in clinical
trials, can only adjust for observed confounding covariates
and cannot adjust for unobserved confounders. Therefore,
propensity analysis reduces but does not eliminate bias in
observational studies. Although propensity analysis allows
matching of variables that are available in large administra-
tive data sets, these data sets have limited information about
patients who are at high anatomic risk. Thus, we were
unable to match patients who were treated for restenosis
after previous CEA, contralateral occlusion, hostile neck, or
a high bifurcation.
Moreover, long-term outcomes could not be addressed
in this analysis because information beyond hospital dis-
charge is not available in these state databases. Although
late complications appear to occur after CEA and CAS, the
frequency of late events appears similar with both proce-
dures, suggesting comparisons based on hospital outcomes
are valid.27
CONCLUSIONS
This analysis brings to question the current role of CAS
for the treatment of both asymptomatic and symptomatic
carotid atherosclerosis. Perioperative stroke/mortality
rates of 8.3% for CAS vs 4.6% for CEA in symptomatic
patients raises questions about the utility of CAS in these
patients. For asymptomatic patients, the nearly equivalent
rate of combined stroke and death of 2.4% for CAS vs 1.9%
for CEA leads us to hypothesize that the less invasive
approach may be an acceptable option in these patients.
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October 2010913.e1 Giacovelli et alTable II, online only. International Classification of Dise
Symptomatic carotid disease (primary or admitting
diagnoses codes)
362.3, 362.8
Comorbidities (present on admission)
Cardiac 093.2, 394,
404.13, 4
426.1, 42
V433, V4
Pulmonary 416, 417.9,
503, 504,
Renal 403.01, 403
440.1, 58
V562, V5
Hypertension 401, 402, 40
Peripheral vascular disease 440.20, 440
443.0, 44
Obesity 278.0
Hyperlipidemia 272
Neurologic disorders 330, 331, 33
344.0, 34
437.0, 43
Diabetes 250
Neck radiology 147, 148, 14
Other cancers 140, 141, 14
158,159,
181, 182,
197, 198,
Complications (developed during hospitalizations)
Stroke 342.90, 362
436, 437.
Transient cerebral ischemia 435.8, 435.9
Nonvascular neurologic complications 293.9, 348.3
781.94, 7
Respiratory complications 31.1, 31.21,
511.9, 51
997.3
Respiratory infection 465.9, 466.0
482.40, 4
485, 486
Urinary infection 599.0
Procedure-related infection 998.5
Cardiac complications 410.00, 410
410.41, 4
410.90, 4
426.13, 4
428.21, 4
Shock 998.0
Renal complications 584, 585, 39
Urinary catheter 591, 788.20
Local complications
Bleeding 285.1, 998.1
Venous thromboembolic 415.1, 453.8
Cranial neuropathy 478.30, 478
Device/patch complications 996.1, 996.6
Hypotension 458.29ases, 9th Revision, Clinical Modification (ICD-9-CM) codes
ICD9-CM code
4, 433.11, 433.31, 434.11, 434.91, 435.8, 435.9, 443.21,434.01
395, 396, 402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.91,
04.93, 412, 413, 414.0, 424, 425.4, 425.5, 425.8, 425.9, 426.0,
6.7, 426.9, 427.0, 427.1, 427.2, 427.3, 427.9, 428, 429.2, V422,
50, V533
490, 491.0, 491.1, 492, 493.0, 493, 494, 495, 496, 500, 501, 502,
505, 506.0, 506.2, 506.4, 506.9, 508.1, 508.8, 508.9
.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93,
2, 583.0, 583.1, 583.2, 583.4, 585, 588.0, V420, V451, V561,
63, V568
3, 404, 405
.21, 440.22, 440.23, 440.24, 440.30, 440.31, 440.32, 440.8, 440.9,
3.1, 443.8, 443.9, 444.22, 447.1, V434
2, 333, 334.0, 334.1, 334.2, 334.4, 334.8, 335, 336, 342, 343,
4.1, 344.2, 344.3, 344.4, 344.5, 344.6, 344.9, 345, 348.1, 348.3,
7.3, 437.4, 437.5, 437.6, 437.7, 438.0, 438.1, 438.2, 438.3, 438.4
9, 161, 193, 230.0, 231.0, 231.1
2, 143, 144, 145, 146, 150, 151, 152, 153, 154, 155, 156, 157,
160, 162, 163, 164, 165, 170, 171,172, 174, 175, 176, 179, 180,
183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 194, 195, 196,
199, 200, 201, 202, 203.0, 238.6
.30, 362.31, 362.32, 362.33, 362.34, 362.84, 431, 434.11, 434.91,
1, 784.3, 997.01, 997.02
0, 348.4, 348.5, 430, 435.0, 435.1, 435.2, 435.3, 780.09, 780.39,
84.5, 997.00, 997.09
31.29, 415.0, 415.11, 415.12, 415.19, 491.21, 496, 507.0, 511.8,
2.1, 518.0, 518.4, 518.5, 518.81, 518.82, 518.84, 786.3, 799.1,
, 481, 482.0, 482.1, 482.2, 482.30, 482.31, 482.32, 482.39,
82.41, 482.49, 482.81, 482.82, 482.83, 482.84, 482.89, 482.9,
.01, 410.10, 410.11, 410.20, 410.21, 410.30, 410.31, 410.40,
10.50, 410.51, 410.60, 410.61, 410.70, 410.71, 410.80, 410.81,
10.91, 411.0, 411.1, 411.81, 411.89, 413.9, 424.1, 426.0, 426.12,
26.53, 427.1, 427.31, 427.32, 427.5, 427.81, 427.89, 428.0,
28.23, 428.31, 428.33, 428.41, 428.43, 785.51, 996.61,997.1
.95
, 788.29, 996.31, 996.64, 996.65, 997.5
1, 998.12, 39.41
, 451.81, 451.83, 451.89, 451.2, 453.2, 453.3, 453.4
.31, 478.32, 781.94, 997.02
0, 996.62, 996.63, 996.74
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stenting (CAS) or carotid endarterectomy (CEA) in New York and California from 2005 to 2007
Predictor CAS OR (95% CI) P CEA OR (95% CI) P
Baseline comorbid conditions
Symptomatic carotid 1.07 (1.50-2.85) .0001 1.43 (1.13-1.80) .003
Congestive heart failure 1.79 (1.17-2.75) .0076 1.67 (1.30-2.15) .0001
Cardiac arrhythmia 0.81 (0.53-1.24) .332 1.33 (1.06-1.65) .012
Valvular 1.06 (0.63-1.18) .828 0.89 (0.65-1.23) .486
Coronary 0.86 (0.63-1.17) .329 1.05 (0.88-1.24) .597
Cerebrovascular 1.30 (0.73-2.32) .369 1.57 (1.13-2.19) .007
Emphysema 1.70 (0.66-4.38) .272 1.29 (0.71-2.32) .405
Other pulmonary 1.08 (0.72-1.64) .705 1.09 (0.88-1.34) .424
Pulmonary circulation 1.94 (0.53-7.02) .314 1.23 (0.62-2.45) .556
Hypertension 1.08 (0.76-1.54) .677 0.95 (0.79-1.15) .619
Hyperlipidemia 1.07 (0.79-1.44) .679 0.94 (0.80-1.14) .497
Paralysis 2.54 (1.49-4.31) .0006 5.51 (3.99-7.61) .0001
Other neurologic disorders 1.10 (0.55-2.22) .789 2.01 (1.39-2.92) .0002
Diabetes 0.89 (0.64-1.25) .518 1.08 (0.90-1.29) .417
Dialysis 0.48 (0.05-4.26) .510 0.55 (0.20-1.53) .249
Renal failure 1.36 (0.84-2.20) .219 1.70 (1.31-2.22) .0001
Lower extremity ischemia 2.99 (0.83-10.77) .094 2.57 (1.42-4.66) .002
Renal atherosclerosis 2.61 (1.10-6.22) .030 1.29 (0.61-2.71) .506
Other vascular atherosclerosis 0.87 (0.53-1.24) .324 1.35 (1.10-1.66) .0005
Lymphoma 1.31 (0.14-9.34) .909 0.78 (0.19-3.22) .733
Metastatic cancer 3.37 (0.98-11.57) .053 3.89 (1.72-8.79) .001
Solid tumor cancer 2.50 (1.10-5.67) .028 1.53 (0.89-2.637) .126
Rheumatoid arthritis 1.78 (0.69-4.61) .229 1.12 (0.62-2.01) .706
Obesity 0.38 (0.13-1.05) .062 1.08 (0.77-1.53) .646
Neck cancer 0.91 (0.38-2.21) .839 1.41 (0.65-3.05) .384
Annual hospital volumea
Very low 2.19 (1.25-3.85) .006 1.08 (0.85-1.38) .518
Low 1.81 (1.02-3.22) .004 0.88 (0.68-1.13) .309
Medium 1.75 (0.97-3.16) .061 0.79 (0.61-1.03) .083
High 1.80 (0.99-3.26) .054 0.83 (0.64-1.09) .176
Very high Reference
Age
65 Reference
65-69 0.95 (0.54-1.68) .855 0.84 (0.62-1.16) .290
70-74 0.99 (0.57-1.71) .972 0.91 (0.67-1.23) .527
75-79 1.41 (0.84-2.35) .191 0.91 (0.67-1.22) .509
80-84 1.36 (0.78-2.37) .272 1.03 (0.75-1.40) .870
85 1.09 (0.65-1.82) .750 1.14 (0.85-1.54) .379
Year of hospitalization 1.00 (0.82-1.22) .994 0.98 (0.88-1.08) .657
Medicare 0.96 (0.68-1.37) .823 1.18 (0.95-1.46) .139
Emergent admission 2.07 (1.50-2.85) .0001 1.72 (1.43-2.08) .0001
CI, Confidence interval; OR, odds ratio.
aVolume in quintiles for CAS: very low, 1-17; low, 18-33; medium, 34-61; high, 62-122; very high 122; for CEA: very low, 1-33; low, 34-57; medium,
58-86; high, 87-123; very high, 123 procedures per year.
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Characteristic
Overall (n  5099)
CAS CEA P
Emergent, % 31.2 31.8 .42
Symptomatic, % 11.0 10.0 .05
Year 2006.1 2006.1 .002
Congestive heart failure, % 9.9 9.5 .49
Cardiac arrhythmia, % 14.0 14.5 .32
Valvular diagnoses, % 7.7 7.8 .90
Coronary diagnoses, % 46.5 47.7 .08
Cerebrovascular disease, % 5.1 5.1 .96
Emphysema, % 1.5 1.8 .35
Other pulmonary disease, % 15.1 14.1 .06
Pulmonary circulation, % 0.9 1.1 .23
Hypertension, % 73.3 74.1 .20
Lipids, % 50.0 51.4 .04
Paralysis, % 2.1 1.9 .50
Other neurologic disorders, % 3.3 3.3 .86
Diabetes, % 2.9 3.3 .54
Dialysis, % 0.5 0.6 .34
Kidney transplant, % 0.1 0.1 .76
Renal failure, % 7.1 7.1 .97
Other renal diagnoses, % 0.0 0.0 .32
Liver disease, % 0.4 0.4 .73
Lower extremity ischemia, % 0.5 0.3 .10
Other vascular atherosclerosis, % 16.2 16.7 .35
Renal atherosclerosis 1.3 1.2 .78
Vascular intestine, % 0.0 0.1 .65
Lymphoma, % 0.3 0.3 .99
Metastatic cancer, % 0.4 0.3 .62
Solid tumor, % 1.4 1.7 .34
Rheumatoid arthritis, % 1.4 1.4 .93
Obesity, % 3.8 4.0 .61
Failure to thrive, % 0.1 0.1 .71
Neck cancer, % 1.9 2.0 .82
Medicare, % 63.6 63.5 .91
CEA volume, %
1-33 22.7 21.6 .03
34-56 18.8 18.9 .85
57-82 23.3 22.3 .08
83-117 18.9 19.2 .57
CAS volume, %
15-30 26.3 25.5 .17
31-56 19.1 17.9 .03
57-110 18.17 19.3 .02
110 11.1 11.5 .39
Hispanic, % 7.5 7.3 .58
Black, % 3.0 3.3 .32
Male gender, % 59.9 59.6 .42
Age, mean (range) y 71.2 (70.9-71.5) 71.9 (71.6-72.2) .005
Propensity score 0.3296662 0.329237 .9232
CAS, Coronary artery stenting; CEA, carotid endarterectomy.
aMean propensity score for each group is shown. C-statistics for overall model to predict CAS vs CEA was 0.875, for symptomatic cohort, 0.865; for
asymptomatic cohort, 0.876.
JOURNAL OF VASCULAR SURGERY
Volume 52, Number 4 Giacovelli et al 913.e4Table IV, online only. Continued
Symptomatic (n  558) Asymptomatic (n  4534)
CAS CEA P CAS CEA P
69.0 68.6 .88 26.1 27.7 .01
2006.1 2006.1 .99 2006.1 2006.1 .20
10.0 12.4 .19 9.6 9.6 .99
16.7 16.8 .93 13.7 14.3 .26
8.6 11.3 .11 7.7 7.3 .34
36.9 39.8 .29 47.3 49.2 .002
5.0 6.3 .34 5.1 5.3 .59
2.0 2.7 .39 1.6 1.6 .85
14.0 16.5 .24 15.0 14.6 .42
0.4 0.2 .56 0.9 0.9 .82
74.2 75.4 .58 73.8 74.3 .30
50.5 54.5 .13 49.4 50.5 .06
14.9 12.0 .13 0.7 0.7 .90
3.4 3.4 .99 3.3 3.2 .73
27.2 25.8 .56 28.5 29.8 .15
0.4 0.5 .65 0.4 0.6 .25
0.0 0.2 .32 0.1 0.1 .32
8.2 8.8 .74 7.0 7.4 .48
0.0 0.0 0.0 0.0 .16
0.4 0.4 .99 0.4 0.4 .99
0.5 0.5 .99 0.5 0.5 .75
13.1 16.5 .10 16.3 17.1 .14
1.3 1.3 .99 1.1 1.1 .74
0.0 0.0 0.0 0.0 .56
0.5 0.4 .65 0.3 0.4 .58
0.4 0.2 .56 0.4 0.4 .73
1.1 0.5 .32 1.5 1.4 .73
2.0 1.3 .35 1.3 1.6 .38
4.8 4.5 .77 3.9 3.9 .94
0.1 0.1 .99
2.2 2.2 .99 1.8 1.7 .57
60.0 59.0 .68 64.3 64.2 .83
24.2 23.1 .62 22.8 21.8 .04
20.4 19.2 .54 18.2 18.5 .55
23.5 24.2 .76 23.5 22.3 .02
17.9 18.6 .73 19.0 18.5 .36
25.8 24.6 .59 26.0 25.5 .36
20.8 21.5 .74 18.9 17.5 .01
15.8 15.9 .93 17.8 19.5 .001
7.0 7.0 .99 12.2 12.2 .95
7.6 8.7 .78 7.5 7.0 .42
3.6 6.1 .10 3.0 2.7 .88
59.9 60.3 .94 59.9 60.2 .83
70.07 (68.8-71.3) 72.5 (71.5-73.5) .005 71.4 (71.1-71.7) 72.0 (71.7-72.4) .03
0.349178 0.348342 .9338 0.327818 0.327286 .9172
